Windlass Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research. According to investment-bankers, they are planning to mop up over Rs 7,000 crore in primary share sales.

Asian peers opened lower as concerns over rising coronavirus cases in Japan continued to weigh on the market. South Korean and Thai stock markets remained shut on Monday. MSCI's broadest index of Asia-Pacific shares outside Japan's Nikkei tanked 1.35 per cent.

New Delhi: It continues to rain IPOs this monsoon season. Dalal Street is all set to see as many as four IPOs hitting the market this week. They include Krsnaa Diagnostics, Devyani International, Exxaro Tiles and Windlas Biotech, which are going to raise close to Rs 3,614 crore between August 4 and 6. Companies are rushing to the primary market to make best of the excessive liquidity and investor optimism. But with four issues opening on the same day, investors who have limited capital to deploy, are in a dilemma as to what to pick and what not. Arijit Malakar, Head of Research (Retail) at As...

The proposed flotation, if successful, would be the largest such offer beating Coal India’s Rs 15,200 crore-IPO in 2010, the country’s largest till date

Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the second consecutive year as several pharma and life sciences companies are lined up to tap the equity markets through IPOs over the next few months, according to investment bankers. Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Ph...